BioBlast Pharma (ORPN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Bioblast Pharma Reports Second Quarter 2016 Financial Results
August 25, 2016 8:02 AM EDTTEL AVIV, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2016.
The Company reported a net loss of $3.685 million for the period, $.22 per share, as compared to $3.686 million, $.26 per share for the second quarter of 2015. The net loss for the first half of 2016 was $8.279 million, $.54 per share as compared to $6.985 million, $.49 per share for the first half of 2015.
Cash and cash equivalents (including short-term bank deposits) totaled $15.7 million at June 30, 2016, compared with... More
